NEXENTIS TECHNOLOGIES INC. Financing Cash Flow
NEXENTIS TECHNOLOGIES INC. (NXTS) reported Financing Cash Flow of $6.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- NEXENTIS TECHNOLOGIES INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $3.95M, a 181.74% increase year-over-year.
- NEXENTIS TECHNOLOGIES INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $2.20M, a 13.27% decline year-over-year.
- NEXENTIS TECHNOLOGIES INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $759.00K, a 70.18% increase year-over-year.
- NEXENTIS TECHNOLOGIES INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $4.16M, a 959.29% increase year-over-year.
- NEXENTIS TECHNOLOGIES INC. net cash provided by (used in) financing activities for fiscal 2025 was $8.86M, a 190.65% increase from fiscal 2024.
- NEXENTIS TECHNOLOGIES INC. net cash provided by (used in) financing activities for fiscal 2024 was $3.05M, a 12.27% decline from fiscal 2023.
- NEXENTIS TECHNOLOGIES INC. net cash provided by (used in) financing activities for fiscal 2023 was $3.47M, a 15.19% decline from fiscal 2022.
- NEXENTIS TECHNOLOGIES INC. net cash provided by (used in) financing activities for fiscal 2022 was $4.09M, a 61.82% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $6.15M 10-Q · filed 2026-08-13 | $6.91M derived: sum of 3 quarters · filed 2026-08-13 | $11.07M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $2.20M 10-Q · filed 2026-05-14 | $2.96M derived: sum of 2 quarters · filed 2026-05-14 | $7.12M derived: sum of 3 quarters · filed 2026-05-14 | $8.52M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $759.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $4.92M derived: sum of 2 quarters · filed 2026-03-31 | $6.32M derived: sum of 3 quarters · filed 2026-08-13 | $8.86M 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | $4.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $5.57M derived: sum of 2 quarters · filed 2026-08-13 | $8.10M 10-Q · filed 2025-11-13 | $8.54M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $3.93M 10-Q · filed 2026-08-13 | $4.38M derived: sum of 3 quarters · filed 2026-08-13 | $4.77M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $2.53M 10-Q · filed 2026-05-14 | $2.98M derived: sum of 2 quarters · filed 2026-05-14 | $3.37M derived: sum of 3 quarters · filed 2026-05-14 | $5.54M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $446.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $839.00K derived: sum of 2 quarters · filed 2026-03-31 | $3.01M derived: sum of 3 quarters · filed 2026-03-31 | $3.05M 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | $393.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.56M derived: sum of 2 quarters · filed 2025-11-13 | $2.60M 10-Q · filed 2025-11-13 | $2.60M 10-Q · filed 2024-11-14 | ||||
| 2024-06-30 | $2.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $2.21M 10-Q · filed 2025-08-14 | $2.21M 10-Q · filed 2024-08-14 | |||||
| 2024-03-31 | $40.00K 10-Q · filed 2025-05-15 | $39.95K 10-Q · filed 2024-05-15 | ||||||
| 2023-12-31 | $3.47M 10-K · filed 2025-03-31 | $3.47M 10-K · filed 2024-04-01 | ||||||
| 2022-12-31 | -$2.50K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $4.10M derived: sum of 2 quarters · filed 2024-04-01 | $4.10M derived: sum of 3 quarters · filed 2024-04-01 | $4.09M 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | $4.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $4.10M derived: sum of 2 quarters · filed 2023-11-14 | $4.10M 10-Q · filed 2023-11-14 | $4.06M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | -$1.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$3.96K 10-Q · filed 2023-08-14 | -$44.98K derived: sum of 3 quarters · filed 2023-08-14 | -$46.96K derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | -$2.02K 10-Q · filed 2023-05-15 | -$43.04K derived: sum of 2 quarters · filed 2023-05-15 | -$45.01K derived: sum of 3 quarters · filed 2023-05-15 | $10.52M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | -$41.02K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$42.99K derived: sum of 2 quarters · filed 2023-03-27 | $10.52M derived: sum of 3 quarters · filed 2023-03-27 | $10.73M 10-K · filed 2023-03-27 | ||||
| 2021-09-30 | -$1.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $10.56M derived: sum of 2 quarters · filed 2022-11-14 | $10.77M 10-Q · filed 2022-11-14 | $10.75M 10-Q · filed 2021-11-15 | $10.87M derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | $10.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $10.77M 10-Q · filed 2022-08-15 | $10.76M 10-Q · filed 2021-08-16 | $10.87M derived: sum of 3 quarters · filed 2022-08-15 | $11.30M derived: sum of 4 quarters · filed 2022-08-15 | |||
| 2021-03-31 | $207.34K 10-Q · filed 2022-05-16 | $204.16K 10-Q · filed 2021-05-18 | $311.76K derived: sum of 2 quarters · filed 2022-05-16 | $735.10K derived: sum of 3 quarters · filed 2022-05-16 | $826.37K derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-12-31 | $104.42K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $527.75K derived: sum of 2 quarters · filed 2022-03-31 | $619.02K derived: sum of 3 quarters · filed 2022-03-31 | $741.76K 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $423.33K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $514.60K derived: sum of 2 quarters · filed 2021-11-15 | $637.34K 10-Q · filed 2021-11-15 | $1.01M derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | $91.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $214.01K 10-Q · filed 2021-08-16 | $590.98K derived: sum of 3 quarters · filed 2021-08-16 | $689.26K derived: sum of 4 quarters · filed 2021-08-16 | ||||
| 2020-03-31 | $122.74K 10-Q · filed 2021-05-18 | $499.71K derived: sum of 2 quarters · filed 2021-05-18 | $598.00K derived: sum of 3 quarters · filed 2021-05-18 | $849.30K derived: sum of 4 quarters · filed 2021-05-18 | ||||
| 2019-12-31 | $376.97K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $475.25K derived: sum of 2 quarters · filed 2021-03-29 | $726.56K derived: sum of 3 quarters · filed 2021-03-29 | $1.18M 10-K · filed 2021-03-29 | ||||
| 2019-09-30 | $98.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $349.59K derived: sum of 2 quarters · filed 2020-11-12 | $800.47K 10-Q · filed 2020-11-12 | |||||
| 2019-06-30 | $251.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $702.18K 10-Q · filed 2020-08-11 | ||||||
| 2019-03-31 | $450.87K 10-Q · filed 2020-05-15 | |||||||
| 2018-12-31 | $912.21K 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |